Study In Women And Men With Metastatic Breast Cancer That Have Overexpression Of ErbB2
Status:
Active, not recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
This is a Phase III study designed to evaluate the response (shrinkage or lack of growth) of
tumors of lapatinib plus paclitaxel compared to paclitaxel plus placebo as first line
metastatic treatment in women and men who have metastatic breast cancer. Patients will be
evaluated for safety and efficacy. Countries include China, Hong Kong, Thailand, Brazil and
Peru.